Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X:
“Bicycle Therapeutics reprioritizes pipeline announcing discontinuation Phase 1/2 Duravelo-3 trial for Bicycle Drug Conj ZELENECTIDE in NECTIN4-amplified breast cancer and NSCLC (Duravelo-4). Patients already enrolled will complete their course of treatment.”
Other articles featuring A. Giordano on OncoDaily.